Molecular Pharmacology
Milano
Via Giovanni Antonio Amadeo, 42, 20133 Milano MI
Our research is aimed at generating the biological background for designing innovative and effective pharmacological therapies through the implementation of new methodological approaches and predictive preclinical tumor models. The research is organized in the following domains:
- Identification of novel therapeutic targets through the multi-dimensional characterization of tumor samples and their validation in preclinical models using genetic and pharmacological approaches to inform the design of novel “biology-driven” therapies for specific tumor histologies or groups of tumors characterized by common molecular alterations. Investigations are focused on factors involved in the tumor-stroma cross-talk, the transcriptional/post-transcriptional regulation of gene expression and the lipid metabolism, as well as chromatin modifiers and non-canonical DNA structures.
- Identification of mechanisms of primary and secondary pharmacological resistance and of collateral vulnerabilities. The molecular characterization of tumor samples from patients resistant to specific treatments and investigations of their modulation on tumor response in preclinical models are exploited to design “hypothesis-driven” strategies that ultimately overcome drug resistance.
- Rational design of novel pharmacological strategies to induce synergistic antitumor effects through the combination of cytotoxic drugs and target-specific agents and evaluation of the cellular/molecular mechanisms underpinning the synergistic interaction.
- “Identification and validation of new therapeutic targets in dedifferentiated liposarcoma through in-depth genomic analysis and patient-derived tumour models”. PI: Sandro Pasquali, Co-PI: Noemi Arrighetti, Ministero della Salute.
- “Genomic and microenvironment factors determine lineage plasticity and tumor aggressiveness in rare mesenchymal and epithelial cancers”. PI: Roberta Sulsenti, Co-PI: Stefano Percio 5x1000 Funds – Fondazione IRCCS Istituto Nazionale dei Tumori.
- “Study of the ALT mechanism in tumors of mesenchymal origin”.
PI: Marco Folini, AIRC. - “Molecular and functional characterization of Dedifferentiated Liposarcoma-derived Extracellular Vesicles”. PI: Doldi Valentina
- Co-PI: Giuliana Cassinelli, 5x1000 Funds – Fondazione IRCCS Istituto Nazionale dei Tumori.
- “Expanding the role of GDF-15 in cancer patients to dissect tumor aggressiveness and patient frailty”. PI: Silvia Stacchiotti, Co-PI Valentina Zuco, 5x1000 Funds – Fondazione IRCCS Istituto Nazionale dei Tumori.
- “Targeting of proteasome-associated and non-associated deubiquitinases to overcome drug resistance of ovarian carcinoma”. PI: Paola Perego, AIRC.
- “Glycolipids-coated colloidal Quantum Dots as optical biosensing platform for selective molecular recognition”. PI: Giovanni Beretta, Ministero dell'Università e della Ricerca.
- “Dissecting immunological effects of neoadjuvant therapies in primary high-risk soft tissue sarcomas”. PI: Sandro Pasquali, Fondazione 13 marzo - AIRC Nex Gen Clinician Scientist.
- “Genomic analysis and personalized preclinical model development to identify novel therapeutic targets and determinants of drug response in soft-tissue sarcomas characterized by chromatin regulator-associated abnormalities”. PI: Anna Maria Frezza, Co-PI: Sandro Pasquali, 5x1000 Funds – Fondazione IRCCS Istituto Nazionale dei Tumori.
Sarcoma Accelerator Consortium
(https://sarcomaaccelerator.org.uk/). PI: Alessandro Gronchi, Co-PI: Nadia Zaffaroni, PreclinicalWorking Group coordinator: Sandro Pasquali, AIRC Accelerator Award.
- “Generation and Characterization of Patient-Derived Preclinical Models of Epithelioid Hemangioendothelioma (EHE) for Therapeutic Assessment and Target Validation”. Co-PIs: Silvia Stacchiotti, Nadia Zaffaroni. The EHE Foundation and the EHE Rare Cancer Charity.
- “Dissection of drug resistance mechanisms in dedifferentiated liposarcoma to identify novel therapeutic targets”. PI: Nadia Zaffaroni, AIRC.
- “Dissecting the role of Tau in ovarian carcinoma pathogenesis and drug resistance”. PI: Paola Perego, Co-PI Giovanni Beretta, PNRR Funds.
- Mail: sandro.pasquali@istitutotumori.mi.it
- Tel: 0223902822
Monday to Friday from 9 a.m. to 6 p.m.
Dott. Pasquali Sandro
Acting Head of Complex Structure
Dott. Folini Marco
Senior Researchers
Prof.ssa Perego Paola Maria Chiara
Senior Researchers
Collaboratori
Nadia Zaffaroni
Ricercatori senior
Giovanni Luca Beretta
Giuliana Cassinelli
Valentina Zuco
Ricercatori junior /Post doc
Noemi Arrighetti
Cristina Corno
Valentina Doldi
Sara Franzese
Stefano Percio
Studenti PHD/Specializzandi/Borsisti
Claudia Aurelio
Alessia Beretta
Eleonora Corbella
Matteo Costantino
Eisa Naghshineh
Giulia Peroni
Pietro Pettinari
Emanuela Russo
Cesare Soffientini
Tecnici
Nives Carenini
Elena Cavadini
Loredana Cleris
Laura Dal Bo
Enrica Favini
Studenti universitari
Suzan Abdulrazak
Beatrice Daverio
Michela Noro
Francesca Peluso
Paolo Santinello
Justine Vidal
Amministrativi
Laura Zanesi
Dissecting immunological effects of neoadjuvant therapies in primary high-risk soft tissue sarcomas
B7-H3 COME POTENZIALE BERSAGLIO PER L'IMMUNOTERAPIA BASATA SUI CAR CONTRO I SARCOMI PEDIATRICI DELL’OSSO E DEI TESSUTI MOLLI
DISSECT THE EFFECTS OF COPZ1 TARGETING: A PROMISING STRATEGY FOR DIFFERENT SOLID TUMORS
Microenvironment-on-chip for chemo-radiotherapy testing
SENESCENCE IN THYROID CANCER PROGRESSION AND THERAPY RESISTANCE: PRECLINICAL STUDIES AND THERAPEUTIC IMPLICATIONS
Last update: 11/06/2025